[KVUE] Kenvue Thesis 2026: Brand Stabilization + Tylenol/Listerine Recovery + Starboard Activist Engagement Test Post-J&J Spin Operational Reset

Key Takeaways

• FY2025 revenue ~$15.5-16B (+1-3% YoY) with adj. EPS ~$1.10-1.20 — Kenvue is the consumer health products company spun off from Johnson & Johnson August 2023 (initial IPO May 2023 + tax-free distribution to JNJ shareholders August 2023). FY2025 reflects continued post-spin operational challenges with selected brand category share losses (Tylenol + Listerine + selected facing competitive intensity from store-brand + selected) partially offset by selected operational improvements + Self Care segment recovery + selected pricing.
• 3 segments: Self Care ~$8B (~50%), Skin Health & Beauty ~$4B (~25%), Essential Health ~$3-4B (~25%) — Self Care is dominant economic engine including Tylenol + Motrin + Sudafed + Zyrtec + Benadryl + Imodium + Pepcid + selected; Skin Health & Beauty includes Neutrogena + Aveeno + Clean & Clear + selected; Essential Health includes Listerine + Band-Aid + Johnson's Baby + selected. Selected brands in all 3 segments lost selected category share post-spin (sale & marketing complexity + selected operational disruption from spin-off process).
• CEO Thibaut Mongon since 2023 — Mongon is Kenvue's first independent CEO, taking role at IPO/spin-off; ex-J&J Consumer Health President + selected J&J career background. Mongon's tenure has navigated: spin-off execution + standalone capital structure + selected operational independence + post-spin brand category share losses + Starboard Value activist investor pressure 2024-2025. Capital return: dividend $0.83-0.84/share annual + buybacks $1B FY2025; net debt ~$8-9B; investment-grade Baa1/BBB+ credit rating.
• FY2026 thesis tests three pillars — (1) Brand stabilization across Self Care + Skin Health & Beauty + Essential Health (multiple brands lost selected share post-spin requiring marketing investment + selected innovation); (2) Tylenol + Listerine recovery (top brands experienced selective category share declines post-spin requiring operational reset); (3) Starboard activist engagement (Starboard Value disclosed Kenvue position 2024-2025; selected activist pressure for selected divestitures + selected portfolio rationalization + selected capital return acceleration). Key risks: continued brand share losses extending, activist driving disruptive strategic actions (selected forced divestitures + selected leadership changes), post-spin operational challenges extending multi-years.

Company Background

Kenvue Inc. (NYSE: KVUE), spun off from Johnson & Johnson August 2023 as the standalone consumer health entity, traces its corporate history through Johnson & Johnson's Consumer Health division (multi-decade J&J subsidiary). Headquartered in Skillman, New Jersey, Kenvue operates as world's largest pure-play consumer health products company by revenue with iconic brands across over-the-counter pharmaceuticals + skincare + selected. The spin-off process:

• May 2023: Kenvue IPO ($3.8B raised at $22/share initial price; J&J retained ~89.6% ownership initially)
• August 2023: Tax-free distribution of remaining J&J ownership to J&J shareholders (1.5306 KVUE shares per J&J share)
• Kenvue became fully independent publicly traded entity August 2023

Kenvue's competitive moat rests on three structural advantages: (1) iconic consumer brand portfolio — Tylenol + Motrin + Sudafed + Zyrtec + Benadryl + Imodium + Listerine + Band-Aid + Johnson's Baby + Neutrogena + Aveeno represent multi-decade brand-building with selected #1 or #2 category positions; (2) global distribution network — operations in 165+ countries reaching consumers across diverse markets; (3) R&D + selected innovation pipeline — ~$300-400M annual R&D spend + selected new product launches across categories.

CEO Thibaut Mongon took CEO role at Kenvue IPO/spin-off process (announced 2022, became CEO January 2023 pre-IPO). Mongon's background:

• J&J Consumer Health President (2018-2023)
• Earlier J&J pharmaceutical + consumer health executive roles (~25-year career)
• French-American executive

Mongon's tenure has navigated:

• 2023: Spin-off execution (IPO May + distribution August) + standalone capital structure
• 2024: Post-spin operational challenges + selected brand share losses + Tylenol litigation continuation + selected operational independence
• 2024-2025: Starboard Value activist investor pressure + selected board engagement + selected strategic review

Mongon's strategic positioning emphasizes:

• Operational independence from J&J (separate IT + financial systems + selected marketing organizations)
• Brand investment + selected innovation pipeline
• Selected divestitures (selected non-core brands)
• Capital allocation discipline
• Stakeholder communication (Starboard engagement)

Business Structure

Kenvue reports operations across 3 segments + selected geographic detail:

1. Self Care — ~$8B FY2025 (~50% of revenue):

• Tylenol (acetaminophen pain reliever): #1 brand in pain category; multi-decade leadership
• Motrin (ibuprofen)
• Sudafed (decongestant)
• Zyrtec (antihistamine)
• Benadryl (antihistamine + selected)
• Imodium (anti-diarrhea)
• Pepcid (antacid + heartburn)
• Selected smaller brands: Visine + Tums + selected
• Operating margin ~22-25%
• FY2024-2025 selected category share losses (Tylenol + selected)

2. Skin Health & Beauty — ~$4B FY2025 (~25% of revenue):

• Neutrogena (skincare + sunscreen + cosmetics)
• Aveeno (skincare + body care + selected)
• Clean & Clear (acne + skincare for younger consumers)
• Selected smaller brands: Lubriderm + selected
• Operating margin ~18-22%
• FY2024-2025 selected category competitive intensity from selected indie brands + Sephora-distributed premium

3. Essential Health — ~$3-4B FY2025 (~25% of revenue):

• Listerine (mouthwash + oral care)
• Band-Aid (adhesive bandages — household name)
• Johnson's Baby (selected baby care + adult skincare)
• Aveeno Baby (selected)
• Selected smaller brands: Acuvue contact lenses + selected
• Operating margin ~20-23%
• Selected legacy brand strength + selected category resilience

Geographic Mix (FY2025E):

• North America: ~50% ($7.8-8B)
• EMEA: ~25% ($3.9-4B)
• APAC: ~18% ($2.8-2.9B)
• Latin America: ~7% ($1.1B)

Key Core Metrics

Financial Performance Summary

Segment Performance (FY2025E)

Capital Return Framework (FY2025)

Market Evaluation

Kenvue trades at ~18-22x forward earnings with ~3-4% dividend yield, reflecting consumer health products valuation framework where investors price near-term brand stabilization + activist engagement + post-spin operational reset into multiple. Bull case: brand stabilization materializes through selected marketing investment + selective innovation; Tylenol + Listerine recover category share; Starboard activist engagement drives selected portfolio rationalization + capital return acceleration; selected operational improvements; valuation already reflects selected execution concerns. Bear case: brand share losses extend multi-years (Tylenol + selected continue declining); activist drives disruptive strategic actions (selected forced divestitures may not maximize value); post-spin operational challenges extending; selected litigation overhang (Tylenol litigation continuation post-spin).

Compared to peers: KVUE vs Procter & Gamble (PG, ~$84B revenue with consumer healthcare segment; selected diversified) — PG larger + more diversified; KVUE vs Colgate-Palmolive (CL, ~$20B revenue oral + pet + selected) — selected; KVUE vs Reckitt Benckiser (RKT, similar consumer healthcare focus + selected) — direct UK peer; KVUE vs Haleon (HLN, GSK consumer health spin-off 2022, ~$13B revenue) — direct comparable spin-off; KVUE vs Bayer Consumer Health (selected segment within Bayer BAYRY; selected). Kenvue's iconic brand portfolio + multi-decade category positions provide structural moats but post-spin operational independence + selected category competitive intensity create execution challenges.

Brand Stabilization + Starboard Engagement + Tylenol/Listerine Recovery

The FY2026 thesis for Kenvue centers on brand stabilization across iconic portfolio + Starboard Value activist engagement + Tylenol + Listerine recovery + post-spin operational reset.

Brand Category Share Losses Post-Spin:

• Multiple iconic brands experienced selected share losses post-spin (2023-2025):
  • Tylenol: lost ~1-2 points share in pain category (vs store-brand acetaminophen + selected)
  • Listerine: lost selected share to Crest + selected mouthwash competitors
  • Neutrogena: lost selected premium beauty share
  • Selected smaller brands: selected category pressure
• Causes: spin-off operational disruption (separate IT + marketing systems + selected); reduced J&J corporate marketing budget allocation; selected consumer trade-down to store-brands; selected competitive intensity
• Recovery thesis: Mongon's leadership investing in brand marketing + selected innovation + selective pricing

Starboard Value Activist Engagement:

• Starboard Value disclosed ~$1B+ Kenvue position 2024-2025
• Starboard's typical playbook: portfolio rationalization + selected divestitures + capital return acceleration + selected leadership changes
• Public letters: selected operational concerns + selected portfolio recommendations
• Kenvue board engagement: selected representation discussions + selected strategic review
• Selected divestiture candidates: smaller non-core brands (selected portfolio simplification)
• Activist outcome scenarios:
  • Constructive engagement: Starboard works with Kenvue board; selected divestitures + capital return acceleration
  • Proxy contest: Starboard nominates board members; potential leadership changes
  • Strategic alternatives: selected larger M&A interest from PG/Colgate/Reckitt + selected
• Timeline: selected resolution expected FY2025-2026

Tylenol + Listerine Recovery:

• Tylenol: invested in selected new product launches (Tylenol PM + selected formulations) + selected marketing
• Listerine: selected new product launches + selected marketing investment
• FY2026 expected: Tylenol stable share + selected modest recovery; Listerine selected recovery

Tylenol Litigation Overhang:

• Multi-decade Tylenol product liability litigation continuing post-spin
• Kenvue inherited Tylenol litigation from J&J spin-off (selected indemnification arrangements)
• Selected reserves established + ongoing legal management
• Selected outcomes manageable but persistent overhang

Operational Independence from J&J:

• Separate IT systems + financial reporting + selected marketing
• Selected duplicative costs in early post-spin period (declining)
• Selected operational efficiency improvements expected FY2026-2027

Capital Return:

• Dividend $0.83-0.84/share annual (initiated 2023)
• Buybacks $1B FY2025 (modest)
• Total capital return $2.6B
• Net debt $8-9B
• Investment-grade Baa1/BBB+

FY2026 Outlook:

• Revenue toward $16-16.5B FY2026 (+1-3% on brand stabilization + selected pricing)
• Adj. EPS toward $1.15-1.30 (operational improvements + selected margin recovery)
• Organic sales growth toward +1-3%
• Operating margin toward 22-24%
• FCF $2.5-3.0B
• Capital return $2.5-3B (dividend + buybacks; potentially accelerated with Starboard engagement)
• Dividend toward $0.85-0.92/share (modest increase)
• FY2027 outlook (post-Starboard resolution): revenue $16.5-17.5B, adj. EPS $1.30-1.50, capital return $3-4B if accelerated

Key Risks:

• Continued brand share losses extending (Tylenol + Listerine + selected continued declines)
• Activist driving disruptive strategic actions (selected forced divestitures may not maximize value; selected leadership changes)
• Post-spin operational challenges extending multi-years
• Tylenol litigation expanding (selected adverse jury verdicts + selected)
• Selected currency volatility (international ~50% revenue)
• Selected commodity input cost inflation
• Selected category competitive intensity sustained (store-brand + selected indie brand competition)
• Selected consumer health category maturity

FY2026 Watch Items:

• Tylenol + Listerine category share trajectory
• Starboard engagement outcome (constructive vs proxy contest vs strategic alternatives)
• Operating margin trajectory (target 22-24%)
• Brand category share metrics across portfolio
• Capital return execution
• Selected divestiture announcements

Kenvue's FY2026 thesis is straightforward: brand stabilization across iconic portfolio + Starboard Value activist engagement + Tylenol + Listerine recovery + post-spin operational reset = stabilized growth + capital return acceleration potential. Validation: brand share stabilizes + Starboard engagement constructive + capital return delivered = thesis intact. Failure mode: continued brand share losses + activist disruption + post-spin operational challenges extending = consumer health cycle compression Kenvue cannot fully insulate against despite iconic brand portfolio + multi-decade category positions.